The acquisition of Shanghai-based Greenbot Pharma by a leading biopharmaceutical firm focuses on advancing Alzheimer's disease treatment amidst growing demand and an aging population in China.
Target Information
The target of this acquisition is Greenbot Pharma, a Shanghai-based biotechnology firm primarily engaged in the development of biopharmaceuticals. The company specializes in producing innovative drugs, particularly focusing on Alzheimer’s Disease (AD), which is a progressive neurodegenerative disease impacting memory and cognitive functions.
An estimated 140 million patients currently suffer from Alzheimer’s globally, and it has become a significant public health concern due to its high prevalence and the inadequate treatment options available. The acquisition will enable the acquiring company to expand its portfolio and potentially develop new treatments specifically tailored for Alzheimer's care.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
China's pharmaceutical industry has been experiencing tremendous growth and transformation, largely driven by an increasing aging population and rising chronic disease prevale
Similar Deals
Adicon Holdings Limited → Crown Bioscience Inc.
2026
Boehringer Ingelheim
invested in
Green Mountain Pharmaceuticals
in 2025
in a Other deal
Disclosed details
Transaction Size: $2,112M
Enterprise Value: $2,112M
Equity Value: $2,112M